News GSK grows pipeline with 35Pharma takeover, Frontier deal GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.
News Roche trial offers hope to patients with rare kidney disease A study of Roche's Gazyva has raised the prospect of a first approved therapy for the rare kidney disorder primary membranous nephropathy.
R&D Xenotransplantation at the brink of breakthrough: A new era ... In a landmark procedure performed at Massachusetts General Hospital (MGH) on 25th January 2025, a 66-year-old man with end-stage renal disease (ESRD) received a genetically modif
News Novartis gets FDA nod for second of three IgAN drugs Novartis has claimed accelerated approval in the US for Vanrafia, one of a trio of drugs it hopes will revolutionise the treatment of IgA nephropathy.
News Fabhalta is first FDA-approved therapy for rare disease C3G Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.
News Two more biotechs, Metsera and Maze, cross IPO finish line Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.